Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Boström PJ[au]:

Search results

Items: 1 to 50 of 87

2.

Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.

Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A; FinnProstate Group.

Eur Urol. 2019 Jul 17. pii: S0302-2838(19)30525-1. doi: 10.1016/j.eururo.2019.07.001. [Epub ahead of print]

PMID:
31375279
3.

Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization.

Toivonen J, Montoya Perez I, Movahedi P, Merisaari H, Pesola M, Taimen P, Boström PJ, Pohjankukka J, Kiviniemi A, Pahikkala T, Aronen HJ, Jambor I.

PLoS One. 2019 Jul 8;14(7):e0217702. doi: 10.1371/journal.pone.0217702. eCollection 2019.

4.

Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells.

Kettunen K, Boström PJ, Lamminen T, Heinosalo T, West G, Saarinen I, Kaipio K, Rantala J, Albanese C, Poutanen M, Taimen P.

Eur Urol. 2019 Jun 27. pii: S0302-2838(19)30501-9. doi: 10.1016/j.eururo.2019.06.016. [Epub ahead of print]

5.

Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial.

Sell V, Ettala O, Montoya Perez I, Järvinen R, Pekkarinen T, Vaarala M, Seppänen M, Liukkonen T, Marttila T, Aaltomaa S, Kaasinen E, Boström PJ.

World J Urol. 2019 Jun 8. doi: 10.1007/s00345-019-02841-4. [Epub ahead of print]

PMID:
31177305
6.

Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.

Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, Kiviniemi A, Kähkönen E, Perez IM, Seppänen M, Rannikko A, Oksanen O, Riikonen J, Vimpeli SM, Kauko T, Merisaari H, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Aronen HJ, Boström PJ.

PLoS Med. 2019 Jun 3;16(6):e1002813. doi: 10.1371/journal.pmed.1002813. eCollection 2019 Jun.

7.

Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study.

Salminen AP, Koskinen I, Perez IM, Hurme S, Murtola TJ, Vaarala MH, Nykopp TK, Seppänen M, Isotalo T, Marttila T, Levomäki L, Becker S, Anttinen M, Liukkonen T, Säily M, Pogodin-Hannolainen D, Viitanen J, Palmberg C, Ottelin J, Sairanen J, Ettala OO, Boström PJ.

Eur Urol Oncol. 2018 Dec;1(6):525-530. doi: 10.1016/j.euo.2018.06.014. Epub 2018 Jul 14.

PMID:
31158099
8.

SORLA regulates endosomal trafficking and oncogenic fitness of HER2.

Pietilä M, Sahgal P, Peuhu E, Jäntti NZ, Paatero I, Närvä E, Al-Akhrass H, Lilja J, Georgiadou M, Andersen OM, Padzik A, Sihto H, Joensuu H, Blomqvist M, Saarinen I, Boström PJ, Taimen P, Ivaska J.

Nat Commun. 2019 May 28;10(1):2340. doi: 10.1038/s41467-019-10275-0.

9.

IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy.

Merisaari H, Jambor I, Ettala O, Boström PJ, Montoya Perez I, Verho J, Kiviniemi A, Syvänen K, Kähkönen E, Eklund L, Pahikkala T, Vainio P, Saunavaara J, Aronen HJ, Taimen P.

J Magn Reson Imaging. 2019 Mar 22. doi: 10.1002/jmri.26727. [Epub ahead of print]

PMID:
30903647
10.

Progress towards a Nordic standard for the investigation of hematuria: 2019.

Malmström PU, Skaaheim Haug E, Boström PJ, Gudjónsson S, Bjerggaard Jensen J.

Scand J Urol. 2019 Feb;53(1):1-6. doi: 10.1080/21681805.2018.1555187. Epub 2019 Jan 14.

PMID:
30636472
11.

Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer.

Koivisto MK, Tervahartiala M, Kenessey I, Jalkanen S, Boström PJ, Salmi M.

Carcinogenesis. 2019 Mar 12;40(1):84-92. doi: 10.1093/carcin/bgy154.

PMID:
30395172
12.

ANO7 is associated with aggressive prostate cancer.

Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J.

Int J Cancer. 2018 Nov 15;143(10):2479-2487. doi: 10.1002/ijc.31746. Epub 2018 Sep 22.

13.

Tournament leave-pair-out cross-validation for receiver operating characteristic analysis.

Montoya Perez I, Airola A, Boström PJ, Jambor I, Pahikkala T.

Stat Methods Med Res. 2018 Aug 20:962280218795190. doi: 10.1177/0962280218795190. [Epub ahead of print]

PMID:
30126322
14.

11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial).

Salminen A, Jambor I, Merisaari H, Ettala O, Virtanen J, Koskinen I, Veskimae E, Sairanen J, Taimen P, Kemppainen J, Minn H, Boström PJ.

Cancer Imaging. 2018 Aug 2;18(1):25. doi: 10.1186/s40644-018-0158-4.

15.

Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment.

Nurminen P, Ettala O, Seppänen M, Taimen P, Boström PJ, Kaipia A.

BJU Int. 2019 Feb;123(2):246-251. doi: 10.1111/bju.14470. Epub 2018 Aug 12.

PMID:
29959824
16.

Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.

Knuuttila M, Mehmood A, Mäki-Jouppila J, Ryberg H, Taimen P, Knaapila J, Ettala O, Boström PJ, Ohlsson C, Venäläinen MS, Laiho A, Elo LL, Sipilä P, Mäkelä SI, Poutanen M.

Endocr Relat Cancer. 2018 Sep;25(9):807-819. doi: 10.1530/ERC-18-0148. Epub 2018 May 17.

PMID:
29773553
17.

Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study.

Knaapila J, Kallio H, Hakanen AJ, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Gunell M, Boström PJ.

BJU Int. 2018 Aug;122(2):203-210. doi: 10.1111/bju.14198. Epub 2018 Apr 6.

18.

Time trends and occupational variation in the incidence of testicular cancer in the Nordic countries.

Ylönen O, Jyrkkiö S, Pukkala E, Syvänen K, Boström PJ.

BJU Int. 2018 Sep;122(3):384-393. doi: 10.1111/bju.14148. Epub 2018 Mar 1.

PMID:
29460991
19.

New prostate cancer grade grouping system predicts survival after radical prostatectomy.

Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.

Hum Pathol. 2018 May;75:159-166. doi: 10.1016/j.humpath.2018.01.027. Epub 2018 Feb 13. No abstract available.

20.

Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort.

Knaapila J, Gunell M, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Hakanen AJ, Boström PJ.

Eur Urol Focus. 2019 May;5(3):443-448. doi: 10.1016/j.euf.2017.12.001. Epub 2017 Dec 20.

PMID:
29275146
21.

Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).

Jambor I, Kuisma A, Kähkönen E, Kemppainen J, Merisaari H, Eskola O, Teuho J, Perez IM, Pesola M, Aronen HJ, Boström PJ, Taimen P, Minn H.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):355-364. doi: 10.1007/s00259-017-3875-1. Epub 2017 Nov 16.

PMID:
29147764
22.

The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.

Seikkula HA, Kaipia AJ, Ryynänen H, Seppä K, Pitkäniemi JM, Malila NK, Boström PJ.

Int J Cancer. 2018 Mar 1;142(5):891-898. doi: 10.1002/ijc.31109. Epub 2017 Oct 31.

23.

Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer.

Tervahartiala M, Taimen P, Mirtti T, Koskinen I, Ecke T, Jalkanen S, Boström PJ.

Sci Rep. 2017 Oct 4;7(1):12682. doi: 10.1038/s41598-017-12892-5.

24.

Non-muscle-invasive bladder cancer: a vision for the future.

Malmström PU, Agrawal S, Bläckberg M, Boström PJ, Malavaud B, Zaak D, Hermann GG.

Scand J Urol. 2017 Apr;51(2):87-94. doi: 10.1080/21681805.2017.1283359. Epub 2017 Feb 7. Review.

PMID:
28535714
25.

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR.

J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14.

26.

Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA.

Seikkula HA, Kaipia AJ, Rantanen ME, Pitkäniemi JM, Malila NK, Boström PJ.

Acta Oncol. 2017 Jul;56(7):971-977. doi: 10.1080/0284186X.2017.1288298. Epub 2017 Feb 13.

PMID:
28406044
27.

Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).

Jambor I, Boström PJ, Taimen P, Syvänen K, Kähkönen E, Kallajoki M, Perez IM, Kauko T, Matomäki J, Ettala O, Merisaari H, Kiviniemi A, Dean PB, Aronen HJ.

J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. doi: 10.1002/jmri.25641. Epub 2017 Feb 6.

PMID:
28165653
28.

Erratum: Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.

Laajala TD, Seikkula H, Seyednasrollah F, Mirtti T, Boström PJ, Elo LL.

Sci Rep. 2017 Jan 19;7:40835. doi: 10.1038/srep40835. No abstract available.

29.

Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study.

Ginsburg SB, Algohary A, Pahwa S, Gulani V, Ponsky L, Aronen HJ, Boström PJ, Böhm M, Haynes AM, Brenner P, Delprado W, Thompson J, Pulbrock M, Taimen P, Villani R, Stricker P, Rastinehad AR, Jambor I, Madabhushi A.

J Magn Reson Imaging. 2017 Jul;46(1):184-193. doi: 10.1002/jmri.25562. Epub 2016 Dec 19.

30.

Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.

Laajala TD, Seikkula H, Seyednasrollah F, Mirtti T, Boström PJ, Elo LL.

Sci Rep. 2016 Nov 2;6:36161. doi: 10.1038/srep36161. Erratum in: Sci Rep. 2017 Jan 19;7:40835.

31.

Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.

Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH.

J Urol. 2016 Dec;196(6):1627-1633. doi: 10.1016/j.juro.2016.06.017. Epub 2016 Jun 14.

PMID:
27312316
32.

Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.

Lahdensuo K, Erickson A, Saarinen I, Seikkula H, Lundin J, Lundin M, Nordling S, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.

Mod Pathol. 2016 Dec;29(12):1565-1574. doi: 10.1038/modpathol.2016.154. Epub 2016 Aug 26.

33.

Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy.

Boström PJ, Mirtti T, van Rhijn B, Fleshner NE, Finelli A, Laato M, Jewett MA, Moore MJ, Sridhar S, Nurmi M, Tannock IF, Zlotta AR.

Bladder Cancer. 2016 Apr 27;2(2):263-272.

34.

Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy.

Boström PJ, Thoms J, Sykes J, Ahmed O, Evans A, van Rhijn BW, Mirtti T, Stakhovskyi O, Laato M, Margel D, Pintilie M, Kuk C, Milosevic M, Zlotta AR, Bristow RG.

Bladder Cancer. 2016 Jan 7;2(1):101-109.

35.

Correction: Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.

Alinezhad S, Väänänen RM, Mattsson J, Li Y, Tallgrén T, Tong Ochoa N, Bjartell A, Åkerfelt M, Taimen P, Boström PJ, Pettersson K, Nees M.

PLoS One. 2016 Jun 21;11(6):e0158255. doi: 10.1371/journal.pone.0158255. eCollection 2016.

36.

Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method.

Ginsburg SB, Taimen P, Merisaari H, Vainio P, Boström PJ, Aronen HJ, Jambor I, Madabhushi A.

J Magn Reson Imaging. 2016 Dec;44(6):1405-1414. doi: 10.1002/jmri.25330. Epub 2016 Jun 10.

37.

Update on novel imaging techniques for the detection of lymph node metastases in bladder cancer.

Salminen AP, Jambor I, Syvanen KT, Bostrom PJ.

Minerva Urol Nefrol. 2016 Apr;68(2):138-49. Review.

38.

Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.

Alinezhad S, Väänänen RM, Mattsson J, Li Y, Tallgrén T, Tong Ochoa N, Bjartell A, Åkerfelt M, Taimen P, Boström PJ, Pettersson K, Nees M.

PLoS One. 2016 May 19;11(5):e0155901. doi: 10.1371/journal.pone.0155901. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0158255.

39.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

40.

Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.

Alinezhad S, Väänänen RM, Ochoa NT, Vertosick EA, Bjartell A, Boström PJ, Taimen P, Pettersson K.

BMC Urol. 2016 Feb 29;16:10. doi: 10.1186/s12894-016-0128-8.

41.

Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction.

Merisaari H, Movahedi P, Perez IM, Toivonen J, Pesola M, Taimen P, Boström PJ, Pahikkala T, Kiviniemi A, Aronen HJ, Jambor I.

Magn Reson Med. 2017 Mar;77(3):1249-1264. doi: 10.1002/mrm.26169. Epub 2016 Feb 28.

PMID:
26924552
42.

Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.

Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Boström PJ, Alanen K, Nurmi M, Nees M, Härkönen P.

Int J Cancer. 2016 Jul 1;139(1):140-52. doi: 10.1002/ijc.30048. Epub 2016 Mar 12.

43.

Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care.

Riikonen J, Kaipia A, Petas A, Horte A, Koskimäki J, Kähkönen E, Boström PJ, Paananen I, Kuisma J, Santti H, Matikainen M, Rannikko A.

Scand J Urol. 2016 Jun;50(3):149-54. doi: 10.3109/21681805.2016.1142471. Epub 2016 Feb 16.

PMID:
26881411
44.

Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.

Alinezhad S, Väänänen RM, Tallgrén T, Perez IM, Jambor I, Aronen H, Kähkönen E, Ettala O, Syvänen K, Nees M, Kallajoki M, Taimen P, Boström PJ, Pettersson K.

Urol Oncol. 2016 Jun;34(6):255.e15-22. doi: 10.1016/j.urolonc.2015.12.014. Epub 2016 Feb 5.

PMID:
26857646
45.

Lymph node imaging in bladder cancer.

Salminen AP, Jambor I, Syvänen KT, Boström PJ.

Minerva Urol Nefrol. 2015 Dec 18. [Epub ahead of print]

PMID:
26684180
46.

[PSA and blood test diagnostics of prostate cancer].

Seikkula H, Pettersson K, Boström PJ.

Duodecim. 2015;131(17):1547-52. Review. Finnish.

PMID:
26548101
47.

Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression.

Saarinen I, Mirtti T, Seikkula H, Boström PJ, Taimen P.

PLoS One. 2015 Oct 15;10(10):e0140671. doi: 10.1371/journal.pone.0140671. eCollection 2015.

48.

Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.

Väänänen RM, Ochoa NT, Boström PJ, Taimen P, Pettersson K.

BMC Urol. 2015 Aug 21;15:88. doi: 10.1186/s12894-015-0077-7.

49.

Diffusion-weighted imaging of prostate cancer: effect of b-value distribution on repeatability and cancer characterization.

Merisaari H, Toivonen J, Pesola M, Taimen P, Boström PJ, Pahikkala T, Aronen HJ, Jambor I.

Magn Reson Imaging. 2015 Dec;33(10):1212-1218. doi: 10.1016/j.mri.2015.07.004. Epub 2015 Jul 26.

PMID:
26220861
50.

Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer.

Boström MM, Irjala H, Mirtti T, Taimen P, Kauko T, Ålgars A, Jalkanen S, Boström PJ.

PLoS One. 2015 Jul 21;10(7):e0133552. doi: 10.1371/journal.pone.0133552. eCollection 2015.

Supplemental Content

Loading ...
Support Center